At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SPRY ARS PHARMACEUTICALS INC
Trading 12-11 14:17:48 EST
11.36
+0.92
+8.81%
High11.45Low10.40Vol1.32M
Open10.46D1 Closing10.44Amplitude10.06%
Mkt Cap1.12BTradable Cap627.87MTotal Shares98.85M
T/O14.53MT/O Rate2.39%Tradable Shares55.27M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares
Reuters  ·  11-15
ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares
ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $25 From $28
THOMSON REUTERS  ·  11-14
ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $25 From $28
Stock Track | ARS Pharmaceuticals Surges 7.34% Pre-Market on Strong Q3 Revenue, Despite Wider Losses
Stock Track  ·  11-10
Stock Track | ARS Pharmaceuticals Surges 7.34% Pre-Market on Strong Q3 Revenue, Despite Wider Losses
Stock Track | ARS Pharmaceuticals Soars 7.34% Pre-Market on Strong Q3 Results and neffy Sales Growth
Stock Track  ·  11-10
Stock Track | ARS Pharmaceuticals Soars 7.34% Pre-Market on Strong Q3 Results and neffy Sales Growth
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss
MT Newswires Live  ·  11-10
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss
ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate
Benzinga  ·  11-10
ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate
ARS Pharmaceuticals Q3 Net Income USD -51.151 Million
THOMSON REUTERS  ·  11-10
ARS Pharmaceuticals Q3 Net Income USD -51.151 Million
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for Neffy® (Epinephrine Nasal Spray)
THOMSON REUTERS  ·  11-10
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for Neffy® (Epinephrine Nasal Spray)
Press Release: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy(R) (epinephrine nasal spray)
Dow Jones  ·  11-10
Press Release: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy(R) (epinephrine nasal spray)
ARS Pharma Launches GET Neffy® on US for Patients With Severe Allergic Reactions to Improve Access to Neffy (Epinephrine Nasal Spray)
THOMSON REUTERS  ·  11-04
ARS Pharma Launches GET Neffy® on US for Patients With Severe Allergic Reactions to Improve Access to Neffy (Epinephrine Nasal Spray)
ARS Pharmaceuticals resumed with a Buy at Roth Capital
TIPRANKS  ·  11-04
ARS Pharmaceuticals resumed with a Buy at Roth Capital
ARS Pharmaceuticals Inc. to Release Third Quarter 2025 Financial Results
Reuters  ·  11-03
ARS Pharmaceuticals Inc. to Release Third Quarter 2025 Financial Results
ARS Pharmaceuticals Reports Real-World Success of Intranasal Epinephrine neffy in Treating Anaphylaxis
Reuters  ·  11-03
ARS Pharmaceuticals Reports Real-World Success of Intranasal Epinephrine neffy in Treating Anaphylaxis
ARS Pharmaceuticals Says European Patent Office Upholds Nasal Spray Epinephrine Patent
MT Newswires Live  ·  10-08
ARS Pharmaceuticals Says European Patent Office Upholds Nasal Spray Epinephrine Patent
European Patent Office Upholds ARS Patent for Nasal Spray to Treat Allergic Reaction
Dow Jones  ·  10-08
European Patent Office Upholds ARS Patent for Nasal Spray to Treat Allergic Reaction
BRIEF-ARS Pharmaceuticals Receives Favorable Decision From European Patent Office On Patent Related To Neffy® (Epinephrine Nasal Spray)
Reuters  ·  10-08
BRIEF-ARS Pharmaceuticals Receives Favorable Decision From European Patent Office On Patent Related To Neffy® (Epinephrine Nasal Spray)
ARS Pharmaceuticals : Global Intellectual Property Portfolio Related to Neffy Provides Coverage Until at Least 2039
THOMSON REUTERS  ·  10-08
ARS Pharmaceuticals : Global Intellectual Property Portfolio Related to Neffy Provides Coverage Until at Least 2039
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility from RA Capital and OMERS Life Sciences to Accelerate neffy® Commercialization
Reuters  ·  09-30
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility from RA Capital and OMERS Life Sciences to Accelerate neffy® Commercialization
ARS Pharmaceuticals Secures up to $250 Million Loan Facility With Ra Capital Management and Omers Life Sciences to Accelerate U.S. Commercialization of Neffy®
THOMSON REUTERS  ·  09-30
ARS Pharmaceuticals Secures up to $250 Million Loan Facility With Ra Capital Management and Omers Life Sciences to Accelerate U.S. Commercialization of Neffy®
ARS Pharmaceuticals Inc - ARS Pharma Borrows Initial $100 Mln to Accelerate Neffy Growth
THOMSON REUTERS  ·  09-30
ARS Pharmaceuticals Inc - ARS Pharma Borrows Initial $100 Mln to Accelerate Neffy Growth

Introduction

Company Name.
ARS PHARMACEUTICALS INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.
Issue price:
--